PBC vs PSC (Cholestatic Liver Disease)

PBC and PSC are both cholestatic liver diseases, but they're distinct in almost every clinically relevant way — demographics, duct involvement, antibodies, histology, associations, and cancer risk. USMLE Step 1 loves this comparison because students routinely swap details between the two. The exam tests this through direct recall (which antibody goes with which?), clinical vignette application (middle-aged woman with pruritis and elevated ALP — what's the diagnosis?), and passage-based questions where you have to identify the condition from lab values, biopsy findings, or imaging descriptions. The trickiest part is that both conditions present with cholestatic LFTs (elevated ALP, GGT, conjugated bilirubin), so the differentiator is always the clinical context — not just the liver numbers.

The two most common errors are demographic swapping and duct-level confusion. Students instinctively link 'biliary' with large ducts and forget that PBC actually destroys small intrahepatic bile ducts through granulomatous inflammation. Meanwhile PSC — which is the one that sounds more 'systemic' — is the one causing beading of large intra- and extrahepatic ducts on MRCP. The second reliable trap is antibodies: AMA belongs to PBC, p-ANCA belongs to PSC. These get flipped constantly under pressure.

USMLE Step 1 also tests management implications and downstream cancer risk. PSC is the one associated with ulcerative colitis and carries a major risk of cholangiocarcinoma — this is a surveillance question. PBC is treated with ursodeoxycholic acid and is associated with other autoimmune conditions (Sjögren's, CREST). If a question gives you a young man with IBD, elevated ALP, and beading on MRCP — that's PSC. If it's a middle-aged woman with pruritis, xanthomas, and positive AMA — that's PBC. Lock in those anchors and the rest follows.